These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26501781)

  • 1. Matched Peptides: Tuning Matched Molecular Pair Analysis for Biopharmaceutical Applications.
    Fuchs JE; Wellenzohn B; Weskamp N; Liedl KR
    J Chem Inf Model; 2015 Nov; 55(11):2315-23. PubMed ID: 26501781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
    Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
    Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
    Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL
    Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An iterative approach to class II predictions.
    Mallios RR
    Methods Mol Biol; 2007; 409():341-53. PubMed ID: 18450013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding.
    Zarutskie JA; Sato AK; Rushe MM; Chan IC; Lomakin A; Benedek GB; Stern LJ
    Biochemistry; 1999 May; 38(18):5878-87. PubMed ID: 10231540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of a structural homology model for a class II histocompatibility protein, HLA-DR1: comparison to the crystal structure.
    Nauss JL; Reid RH; Sadegh-Nasseri S
    J Biomol Struct Dyn; 1995 Jun; 12(6):1213-33. PubMed ID: 7669268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex.
    Schlundt A; Günther S; Sticht J; Wieczorek M; Roske Y; Heinemann U; Freund C
    J Mol Biol; 2012 Oct; 423(3):294-302. PubMed ID: 22820093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
    Xu M; Jackson R; Adams S; Humphreys RE
    Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins.
    Zavala-Ruiz Z; Strug I; Anderson MW; Gorski J; Stern LJ
    Chem Biol; 2004 Oct; 11(10):1395-402. PubMed ID: 15489166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides.
    Ishioka GY; Adorini L; Guery JC; Gaeta FC; LaFond R; Alexander J; Powell MF; Sette A; Grey HM
    J Immunol; 1994 May; 152(9):4310-9. PubMed ID: 8157954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1.
    Natarajan SK; Stern LJ; Sadegh-Nasseri S
    J Immunol; 1999 Mar; 162(6):3463-70. PubMed ID: 10092802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperativity during the formation of peptide/MHC class II complexes.
    Anderson MW; Gorski J
    Biochemistry; 2005 Apr; 44(15):5617-24. PubMed ID: 15823020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrapeptide derived inhibitors of complexation of a class II MHC: the peptide backbone is not inviolate.
    Jones AB; Acton JJ; Rivetna MN; Cummings RT; Cubbon RM; Nichols EA; Schwartz CD; Wicker LS; Hermes JD
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2109-14. PubMed ID: 10450991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC class II function preserved by low-affinity peptide interactions preceding stable binding.
    Sadegh-Nasseri S; Stern LJ; Wiley DC; Germain RN
    Nature; 1994 Aug; 370(6491):647-50. PubMed ID: 8065450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A site for CD4 binding in the beta 1 domain of the MHC class II protein HLA-DR1.
    Brogdon J; Eckels DD; Davies C; White S; Doyle C
    J Immunol; 1998 Nov; 161(10):5472-80. PubMed ID: 9820523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The inhibitory effect of hyporesponsive peptide on human leukocyte antigen-DRbeta1 specific T cell activation].
    Zhou Q; Cheng YJ; Li ZG; Zhou WH; Lu HS
    Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1505-9. PubMed ID: 14521731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computer design of T-cell agonist or antagonist glycopeptides: the effect of sugar identity and anomeric configuration on MHC binding.
    Prammer KV; Ertl HC; Otvos L
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):163-70. PubMed ID: 9346848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects on HLA-DR1-specific T-cell activation by influenza virus haemagglutinin-derived peptides.
    Li X; Li R; Li Z
    Tissue Antigens; 2006 Jan; 67(1):45-52. PubMed ID: 16451200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a neural network to identify potential HLA-DR1 binding sites within proteins.
    Bisset LR; Fierz W
    J Mol Recognit; 1993 Mar; 6(1):41-8. PubMed ID: 8251191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
    Ghosh P; Amaya M; Mellins E; Wiley DC
    Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.